START-UP’s monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies within the in vitro diagnostics, pharmaceuticals, research/analytical equipment & supplies, and medical device sectors.
Agendia raises $65mm through late-stage round
A year after withdrawing its IPO filing, molecular diagnostics firm Agendia BV has raised $65mm in what appears to...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.
Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.
Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.
The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.
Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.
The Swiss giant has been talking to the US government about selling medicines directly to patients.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
